[Hypogammaglobulinemia and Multiple Sclerosis - An Overlooked Correlation?]

Area of Science:

• Neurology
• Immunology

Background:

• Hypogammaglobulinemia occurs in 8.1% of multiple sclerosis (MS) patients without immunotherapy and up to 26.4% with immunotherapy.
• This incidence is significantly higher than in the general population, suggesting a potential link.

Purpose of the Study:

• To spotlight the correlation between hypogammaglobulinemia and MS.
• To differentiate between primary and secondary hypogammaglobulinemia in MS patients.
• To emphasize the clinical consequences of hypogammaglobulinemia in MS.

Main Methods:

• Literature review focusing on hypogammaglobulinemia in MS patients.
• Analysis of incidence rates with and without immunotherapy.
• Discussion of primary versus secondary hypogammaglobulinemia, particularly anti-CD20 therapies.

Main Results:

• Elevated prevalence of hypogammaglobulinemia in MS patients compared to the general population.
• Identification of immunotherapy, especially anti-CD20 therapies, as a key factor in secondary hypogammaglobulinemia.
• Recognition of the clinical relevance of this association.

Conclusions:

• Hypogammaglobulinemia is a significant comorbidity in MS patients.
• Understanding the causes and clinical impact of hypogammaglobulinemia is crucial for MS management.
• Further research is warranted to explore this correlation and its implications.